Financial Results for September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Topline grew sharply: standalone revenue from operations jumped about 186% year-on-year for H1 FY26 to ₹3,241.70 lakhs, and consolidated revenue nearly tripled to ₹4,251.27 lakhs from ₹1,358.67 lakhs, helped by the consolidation of newly acquired subsidiary Neuro and Spine Associates. However, profitability collapsed: standalone net profit fell from ₹115.59 lakhs to just ₹9.93 lakhs in H1, while the company swung to a consolidated net loss of ₹785.15 lakhs versus a profit of ₹115.50 lakhs last year. Costs surged, with consolidated employee expenses at ₹1,115 lakhs, depreciation at ₹199.84 lakhs, and finance costs at ₹58.39 lakhs, while the acquired subsidiary alone contributed a loss of roughly ₹763 lakhs for H1. Trade receivables ballooned to ₹1,612.87 lakhs standalone (₹2,153.10 lakhs consolidated), cash and bank balances collapsed, and operating cash flow was deeply negative at ₹(727) lakhs standalone and ₹(1,254) lakhs consolidated. The statutory auditor's review report is clean, with no qualifications or emphasis-of-matter.
The result is a mixed-to-negative read for shareholders: strong revenue scale-up on paper, but heavy losses at the consolidated level, sharp margin compression, mounting receivables, and negative operating cash flows raise concerns about earnings quality and working-capital health. Investors should track whether the acquired hospital business improves and whether the company can convert top-line growth into real cash profits in coming quarters.